Jupiter Neurosciences, Inc.
Key statistics
from XBRL data in SEC filingsAI briefing
from the latest 10-K, 10-Q and 8-K eventsJupiter Neurosciences is a clinical-stage pharmaceutical company developing JOTROL, an enhanced oral resveratrol formulation, and launching a consumer wellness line, Nugevia.
What they do
The Company is focused on developing treatments for neuroinflammation via its proprietary resveratrol platform, JOTROL, targeting CNS disorders such as Parkinson's Disease. It operates through two segments: pharmaceutical development and a consumer-oriented product line, Nugevia, which sells nutritional supplements supporting longevity and wellness. Nugevia products (GLO, MND, PWR) began direct-to-consumer sales in Q4 2025.
Revenue drivers
- Nugevia consumer products — First products (GLO, MND, PWR) available for sale, shipments began Q4 2025 via direct-to-consumer; generated $18,652 revenue in Q1 2026 and $21,796 for full-year 2025.
- JOTROL pharmaceutical pipeline — Phase IIa trial in Parkinson's Disease approved by FDA (Nov 2025), trial not yet started; no revenue from this segment to date.
- Potential out-licensing in Asia — Service agreements with Hong Kong firms and an agreement with Dominant Treasure Health for business development in China, Malaysia, and Singapore; no revenue yet reported from these.
Recent performance
Revenue was minimal: $21,796 in 2025 vs $0 in 2024, with Q1 2026 revenue of $18,652 vs $0 in Q1 2025. Net loss widened to $-8.6M in 2025 from $-2.4M in 2024; Q1 2026 data not provided but balance sheet shows shareholder equity of $-2.8M and total liabilities of $6.7M. Operating cash flow was negative at $-5.4M in 2025. The independent auditor included a going concern explanatory paragraph in the 2025 and 2024 reports, and management concluded substantial doubt exists.
Strategy
Management is advancing JOTROL into a Phase IIa Parkinson's Disease trial, targeting start in Q2 2026, with results anticipated 12 months later. It is also commercializing Nugevia to monetize its science and support clinical trials, marketing in the U.S. and internationally. The Company is pursuing Asian partnerships and out-licensing opportunities, leveraging recent patent approvals in Hong Kong and China and growth in the Traditional Chinese Medicine market. It raised $11M gross proceeds from a public offering in December 2024, and has a Standby Equity Purchase Agreement, though drawing on it may be limited by low trading volume.
Risks
- Going concern uncertainty — Management and auditors have expressed substantial doubt about the Company's ability to continue as a going concern.
- Indebtedness and liquidity — Substantial convertible promissory note debt and limited cash ($3.9M total assets vs $6.7M liabilities as of Q1 2026) may impair operations and increase dilution if draws on the SEPA are made.
- Dependence on Aquanova license — Business depends on an exclusive worldwide license with Aquanova; any adverse development in that agreement could materially harm operations.
- Clinical trial risk — Phase IIa trial may fail to show safety or efficacy; preclinical results may not predict outcomes, and delays are possible.
Outlook
Management expects to start the JOTROL Phase IIa Parkinson's trial in Q2 2026 and report results about 12 months later, with plans to explore additional CNS indications like MCI and Alzheimer's. Nugevia sales are expected to grow as the Company continues its DTC launch and international marketing. However, substantial additional capital is required to fund operations and the trial, and raising it may cause dilution or force program reductions.